Merck Trades Below Peer Value Despite 80% Surge
Merck's stock has experienced an impressive 80% surge over the last 12 months, outperforming the S&P 500. The pharmaceutical giant's market capitalization stands at $376 billion. Yesterday, August 19, 2026, marked a new all-time high for Merck's stock.
The immediate catalyst for this breakout was the clinical success of an experimental mRNA cancer vaccine developed with Moderna (MRNA). This milestone demonstrated significant efficacy and prompted a large influx of buying volume based on its oncology revenue potential. However, yesterday's news validates a broader strategy that has been unfolding over time.
The real driver behind Merck's annual return is how the company has methodically addressed the primary question keeping shareholders awake at night: what happens after the KEYTRUDA patent cliff? For years, the looming loss of exclusivity for the blockbuster drug KEYTRUDA was a significant concern. Merck's management answered this anxiety with a steady drumbeat of clinical and regulatory wins.
The pipeline has delivered tangible results, reframing the company from one facing a patent cliff to one building a reliable bridge for consistent earnings growth. The capstone event was the FDA approval of LIPFENDRA, an oral PCSK9 inhibitor for high cholesterol that disrupts a market dominated by injectables. Clinical data shows this daily pill lowers LDL cholesterol by up to 60% when added to a statin.
The pipeline has also announced positive Phase III results for sac-TMT in endometrial cancer and tulisokibart in ulcerative colitis. Pipeline question marks have become definitive checkmarks, proving the research engine remains highly productive.
With clinical data firming up, management finally quantified the future, projecting a pipeline with greater than $70 billion of commercial opportunity spread across more than 20 new products. This figure acts as a powerful counter-narrative to the impending KEYTRUDA revenue gap. The substantial stock revaluation shows Wall Street now firmly believes this projection.
The valuation provides the true test of this pivot, and at 16x forward earnings, Merck trades at a relatively low multiple compared to its peers. Johnson & Johnson (JNJ) trades at 21.5x forward earnings, while Eli Lilly (LLY) commands 27x. Despite surging over 80% in the past year, Merck's 16x multiple highlights that the stock remains undervalued relative to top-tier peers.